IA
RYTM icon

IFP Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

IFP Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Sell
27
-19
-41% -$1.72K ﹤0.01% 4055
2026
Q1 		$4K Buy
46
+10
+28% +$972 ﹤0.01% 3651
2025
Q4 		$3.85K Buy
36
+17
+89% +$1.8K ﹤0.01% 3545
2025
Q3 		$1.92K Buy
19
+4
+27% +$371 ﹤0.01% 3713
2025
Q2 		$1.2K Buy
+15
New +$918 ﹤0.01% 4153
2025
Q1 		– Sell
-1
Closed -$56 – 4586
2024
Q4 		$56 Buy
+1
New +$55 ﹤0.01% 4225
2022
Q4 		– Sell
-600
Closed -$20K – 4804
2022
Q3 		$20K Buy
+600
New +$11.2K ﹤0.01% 3092

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

IFP Advisors's RYTM Position: Q2 2026 in Review

IFP Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 41% in Q2 2026, selling an estimated $1.72K and leaving 27 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4055.

IFP Advisors first reported a position in RYTM in Q3 2022 and has held it in 7 quarters since. The position peaked at $20K in Q3 2022. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • IFP Advisors held 27 shares of Rhythm Pharmaceuticals worth $3K as of Q2 2026.
  • IFP Advisors sold 19 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.72K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4055 holding.
  • IFP Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
  • IFP Advisors's Rhythm Pharmaceuticals position peaked at $20K in Q3 2022.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.